Molecular analysis has shed light on the diversity and hierarchy of genetic events linked to T
Acknowledgement
LdL is supported by a grant of the Swiss National Foundation.
Must Reads
Heavican, T.B., Bouska, A., Yu,. J, et al. (2019). Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T‐cell lymphoma. Blood 133(15):1664–1676.
Lemonnier, F., Couronné, L., Parrens, M., et al. (2012). Recurrent TET2 mutations in peripheral T‐cell lymphomas correlate with TFH‐like features and adverse clinical parameters. Blood 120(7):1466–1469.
Sakata‐Yanagimoto, M., Enami, T., Yoshida, K. et al. (2014). Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46(2):171–175.
Crescenzo, R., Abate, F., Lasorsa, E. et al. (2015). Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 27(4):516–532.
Gaulard, P., de Leval, L. (2014). The microenvironment in T‐cell lymphomas: emerging themes. Semin Cancer Biol 24:49–60.
References
1 1 Morris, S.W., Kirstein, M.N., Valentine, M.B. et al. (1994). Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non‐Hodgkin's lymphoma. Science 263 (5151): 1281–1284.
2 2 Parrilla Castellar, E.R., Jaffe, E.S., Said, J.W. et al. (2014). ALK‐negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124 (9): 1473–1480.
3 3 Abate, F., da Silva‐Almeida, A.C., Zairs, S. et al. (2017). Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T‐cell lymphomas. Proc Natl Acad Sci U S A 114 (4): 764–769.
4 4 Yoo, H.Y., Sung, M.K., Lee, S.H. et al. (2014). A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 46 (4): 371–375.
5 5 Vallois, D., Dupuy, A., Lemonnier, F. et al. (2018). RNA fusions involving CD28 are rare in peripheral T‐cell lymphomas and concentrate mainly in those derived from follicular helper T cells. Haematologica 103 (8): e360–e363.
6 6 Heavican, T.B., Bouska, A., Yu, J. et al. (2019). Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T‐cell lymphoma. Blood 133 (15): 1664–1676.
7 7 Stephens, P.J., Greenman, C.D., Fu, B. et al. (2011). Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144 (1): 27.
8 8 Boddicker, R.L., Razidlo, G.L., Dasari, S. et al. (2016). Integrated mate‐pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T‐cell lymphoma. Blood 128 (9): 1234–1245.
9 9 Kataoka, K., Shiraishi, Y., Takeda, Y. et al. (2016). Aberrant PD‐L1 expression through 3’‐UTR disruption in multiple cancers. Nature 534 (7607): 402–406.
10 10 Kataoka, K., Miyoshi, H., Sakata, S. et al. (2019). Frequent structural variations involving programmed death ligands in Epstein‐Barr virus‐associated lymphomas. Leukemia 33 (7): 1687–1699.
11 11 Liu, C., Iqbal, J., Teruya‐Feldstein, J. et al. (2013). MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. Blood 122 (12): 2083–2092.
12 12 Valleron, W., Ysebaert, L., Berquet, L. et al. (2012). Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T‐cell lymphoma. Blood 120 (19): 3997–4005.
13 13 Wang, L., Ni, X., Covington, K.R. et al. (2015). Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet 47 (12): 1426–1434.
14 14 Sakata‐Yanagimoto, M., Enami, T., Yoshida, K. et al. (2014). Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46 (2): 171–175.
15 15 Odejide, O., Weigert, O., Lane, A.A. et al. (2014). A targeted mutational landscape of angioimmunoblastic T‐cell lymphoma. Blood 123 (9): 1293–1296.
16 16 Lemonnier, F., Couronné, L., Parrens, M. et al. (2012). Recurrent TET2 mutations in peripheral T‐cell lymphomas correlate with TFH‐like features and adverse clinical parameters. Blood 120 (7): 1466–1469.
17 17 Couronné, L., Bastard, C., and Bernard, O.A. (2012). TET2 and DNMT3A mutations in human T‐cell lymphoma. N Engl J Med 366 (1): 95–96.
18 18 Cairns, R.A., Iqbal, J., Lemonnier, F. et al. (2012). IDH2 mutations are frequent in angioimmunoblastic T‐cell lymphoma. Blood 119 (8): 1901–1903.
19 19 Solary, E., Bernard, O.A., Tefferi, A. et al. (2014). The Ten‐Eleven Translocation‐2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 28 (3): 485–496.
20 20 Kim, S.J., Zhao, H., Hardikar, S. et al. (2013). A DNMT3A mutation common in AML exhibits dominant‐negative effects in murine ES cells. Blood 122 (25): 4086–4089.
21 21 Cairns, R.A. and Mak, T.W. (2013). Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov 3 (7): 730–741.
22 22 Lemonnier, F., Poullot, E., Dupuy, A. et al. (2018). Loss of 5‐hydroxymethylcytosine is a frequent event in peripheral T‐cell lymphomas. Haematologica 103 (3): e115–e118.
23 23 Roberti, A., Dobay, M.P., Bisig, B. et al. (2016). Type II enteropathy‐associated T‐cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nat Commun 7: 12602.
24 24 McKinney, M., Moffitt, A.B., Gaulard, P. et al. (2017). The genetic basis of hepatosplenic T‐cell lymphoma. Cancer Discov 7 (4): 369–379.
25 25 Jiang, L., Gu, Z.H., Yan, Z.X. et al. (2015). Exome sequencing identifies somatic mutations of DDX3X in natural killer/T‐cell lymphoma. Nat Genet 47 (9): 1061–1066.
26 26 Li, Z., Zhang, X., Xue, W. et al. (2019). Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma. Nat Commun 10 (1): 4209–4209.
27 27 Ji, M.M., Huang, Y.H., Huang, J.Y. et al. (2018). Histone modifier gene mutations in peripheral T‐cell lymphoma not otherwise specified. Haematologica 103 (4): 679–687.
28 28 Laurent, C., Nicolae, A., Laurent, C. et al. (2020). Gene alterations in epigenetic modifiers and JAK‐STAT signaling are frequent in breast implant–associated ALCL. Blood 135 (5): 360–370.
29 29 Genovese, G., Kähler, A.K., Handsaker, R.E. et al. (2014). Clonal hematopoiesis and blood‐cancer risk inferred from blood DNA sequence. N Engl J Med 371 (26): 2477–2487.
30 30 Jaiswal, S., Fontanillas, P., Flannick, J. et al. (2014). Age‐related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371 (26): 2488–2498.
31 31 Quivoron, C., Couronné, L., Della Valle, V. et al. (2011). TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human
